LXRX

$1.481.37%0.02

After Hours: 1.51+0.03 +2.03%

Lexicon Pharmaceuticals Inc (LXRX)

Date: O: H: L: C: Vol:

Lexicon Pharmaceuticals Inc stock is traded at $1.48, with a volume of 1,949,171. It is up +1.37% in the last 24 hours and down -18.68% over the past month. Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Previous Close:

$1.46

Open:

$1.50

24h Volume:

1,949,171

Relative Volume:

1.03

Market Cap:

$658.53M

Revenue:

$69.64M

Net Income/Loss:

-$26.09M

P/E Ratio:

EPS:

-$0.0715

Net Cash Flow:

-$38.80M

1W Performance:

-0.34%

1M Performance:

-18.68%

6M Performance:

-7.50%

1Y Performance:

+11.28%

1-Day Range:

$1.46$1.54

1-Week Range:

$1.38$1.54

52-Week Range:

$1.10$2.68

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name

Lexicon Pharmaceuticals Inc

Sector

Healthcare

Industry

Biotechnology

Phone

(281) 863-3000

Address

2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS, USA

Employee

@LexPharma

Next Earnings Date

2026-11-05

Latest SEC Filings

SEC

LXRX's Discussions on X

Market Cap

Revenue

Net Income

Cash Flow

EPS

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-28-26	Initiated	Cantor Fitzgerald	Overweight
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jun-17-24	Initiated	H.C. Wainwright	Buy
Apr-30-24	Initiated	Leerink Partners	Outperform
Mar-07-23	Initiated	Jefferies	Hold
Aug-12-22	Initiated	Piper Sandler	Overweight
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy
Jul-29-19	Downgrade	Stifel	Buy → Hold
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Mar-01-17	Reiterated	H.C. Wainwright	Buy
Mar-01-17	Reiterated	Wedbush	Outperform
Oct-07-16	Initiated	H.C. Wainwright	Buy
Aug-05-16	Reiterated	Wedbush	Outperform
Aug-02-16	Initiated	Citigroup	Buy
Mar-02-16	Reiterated	Wedbush	Outperform
Nov-09-15	Reiterated	Wedbush	Outperform
Sep-28-15	Upgrade	Gabelli & Co	Sell → Hold
Sep-18-15	Downgrade	Gabelli & Co	Hold → Sell
Aug-10-15	Downgrade	JP Morgan	Overweight → Neutral

Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data

Period	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period End Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	49.80	31.08	1.20	0.14	0.30
Cost of revenue USD (M)	0.27	0.62	0.09	0.00	0.00
Gross profit USD (M)	-	-	1.12	-	-
Research and development USD (M)	61.12	84.48	58.89	52.82	55.05
Operating expenses USD (M)	98.71	228.20	172.87	100.90	87.39
Operating income USD (M)	-48.91	-197.12	-171.75	-100.76	-87.09
Income before tax USD (M)	-	-	-171.75	-101.94	-87.76
Income tax expense USD (M)	-	0.00	0.00	-	-
Net income USD (M)	-50.34	-200.40	-177.12	-101.94	-87.76
Basic EPS USD/shares	-0.14	-0.63	-0.80	-0.62	-0.60
Diluted EPS USD/shares	-0.14	-0.63	-0.80	-	-0.60
Basic weighted shares shares (M)	363.05	320.03	221.13	-	-
Diluted weighted shares shares (M)	363.05	320.03	221.13	-	145.65
Selling, general and administrative USD (M)	37.32	143.10	113.98	-	-

Lexicon Pharmaceuticals Inc Stock (LXRX) Insider Trading

Sullivan Diane E.Jun 03 '26
Director
Transaction
Option Exercise
Cost
$0.00
#Shares
89,312
Value ($)
0
#Shares Total
126,122
SOBECKI CHRISTOPHER JJun 03 '26
Director
Transaction
Option Exercise
Cost
$0.00
#Shares
89,312
Value ($)
0
#Shares Total
293,177
Cheung IvanJun 03 '26
Director
Transaction
Option Exercise
Cost
$0.00
#Shares
89,312
Value ($)
0
#Shares Total
89,312
BARKER SAM LJun 03 '26
Director
Transaction
Option Exercise
Cost
$0.00
#Shares
89,312
Value ($)
0
#Shares Total
213,771
Amouyal PhilippeJun 03 '26
Director
Transaction
Option Exercise
Cost
$0.00
#Shares
89,312
Value ($)
0
#Shares Total
374,486
DEBBANE RAYMONDJun 03 '26
Director
Transaction
Option Exercise
Cost
$0.00
#Shares
89,312
Value ($)
0
#Shares Total
1,995,498
Swain Judith LJun 03 '26
Director
Transaction
Option Exercise
Cost
$0.00
#Shares
89,312
Value ($)
0
#Shares Total
174,486
Artal Participations S.a r.l.Apr 30 '26
Director
Transaction
Option Exercise
Cost
$0.00
#Shares
20,421,735
Value ($)
0
#Shares Total
175,156,062
DEBBANE RAYMONDFeb 25 '26
Director
Transaction
Buy
Cost
$1.49
#Shares
2,000
Value ($)
2,980
#Shares Total
1,906,186
DEBBANE RAYMONDFeb 23 '26
Director
Transaction
Buy
Cost
$1.47
#Shares
100,000
Value ($)
147,000
#Shares Total
1,904,186

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Sullivan Diane E.	Director	Jun 03 '26	Option Exercise	$0.00	89,312	0	126,122
SOBECKI CHRISTOPHER J	Director	Jun 03 '26	Option Exercise	$0.00	89,312	0	293,177
Cheung Ivan	Director	Jun 03 '26	Option Exercise	$0.00	89,312	0	89,312
BARKER SAM L	Director	Jun 03 '26	Option Exercise	$0.00	89,312	0	213,771
Amouyal Philippe	Director	Jun 03 '26	Option Exercise	$0.00	89,312	0	374,486
DEBBANE RAYMOND	Director	Jun 03 '26	Option Exercise	$0.00	89,312	0	1,995,498
Swain Judith L	Director	Jun 03 '26	Option Exercise	$0.00	89,312	0	174,486
Artal Participations S.a r.l.	Director	Apr 30 '26	Option Exercise	$0.00	20,421,735	0	175,156,062
DEBBANE RAYMOND	Director	Feb 25 '26	Buy	$1.49	2,000	2,980	1,906,186
DEBBANE RAYMOND	Director	Feb 23 '26	Buy	$1.47	100,000	147,000	1,904,186

Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News

Oct 29, 2026